BioDlink International Company Limited (1875) presented unaudited consolidated financial information for the year ended 31 December 2025. According to the figures extracted from unaudited management accounts, total revenue for 2025 reached RMB 747.65 million, compared to RMB 1.10 billion recorded in 2024. The company reported a net loss of RMB 100.37 million for 2025, reversing from a net profit of RMB 34.76 million the previous year.

In terms of financial position, total net assets as of 31 December 2025 amounted to RMB 625.82 million, down from RMB 729.66 million as of 31 December 2024. Current assets at year-end 2025 stood at RMB 560.92 million, while non-current assets came in at RMB 698.37 million. On the liabilities side, current liabilities totaled RMB 273.52 million and non-current liabilities RMB 359.96 million.

The announcement highlighted that these results remain subject to potential adjustments and external audit. A final audited report covering the same period is expected to be released on 18 March 2026. Shareholders and potential investors are advised to exercise caution when interpreting the unaudited results and dealing in the company’s securities.